Business Wire

LatticeFlow AI Sets a New Standard for AI Governance With Evidence-Based Technical Assessments

17.9.2025 11:51:00 EEST | Business Wire | Press release

Share

LatticeFlow AI, the Swiss deep-tech company advancing trustworthy and compliant AI, today announced the Early Access Program for AI GO!, the first platform that enables AI Governance Operations through deep technical assessments. With this, LatticeFlow AI sets a new standard for AI governance and compliance, enabling organizations to accelerate their AI advantage.

Traditional Governance, Risk and Compliance (GRC) systems, based on checklists, are insufficient to govern complex and rapidly evolving AI systems. LatticeFlow AI GO! provides rigorous, evidence-based assessments that uncover AI risks, generate audit-ready insights, and empower confident decision-making. The platform equips AI risk and compliance teams with the visibility and confidence they need to harness the full potential of GenAI applications, chatbots, and the latest LLMs.

“The only way AI governance can work and scale is when it’s grounded in technical evidence,” said Petar Tsankov, CEO and Co-Founder of LatticeFlow AI. “With AI GO!, enterprises gain the deep insights they need to manage AI risks, prove compliance, and accelerate innovation with confidence.”

Building on its leadership as co-creator of COMPL-AI (the first framework to assess GenAI models against the EU AI Act) and grounded in Swiss precision and scientific rigor, LatticeFlow AI sets a new standard for doing AI governance right. The company transforms complex AI systems into transparent, auditable, and trustworthy insights enterprises can rely on for any framework, standard or regulation, such as NIST, ISO, and the EU AI Act.

More information and demos of LatticeFlow AI GO! are available on this link.

Getting AI Governance Right Through Evidence and Trust

With AI GO!, LatticeFlow AI enables organizations to get AI governance right by combining rigorous technical assessments with the automation required to apply consistent oversight across departments and use cases.

Given its AI-first governance approach, the new platform allows teams to leverage out-of-the box AI risk frameworks, such as the EU AI Act, or add their own, custom AI risk frameworks, ensuring AI governance aligns with business needs.

In addition, LatticeFlow AI GO! is extensible across modalities and applications, from GenAI, LLMs, chatbots, to Computer Vision and Tabular models, providing a unified way to evaluate performance, safety, and compliance for any AI system.

Finally, the new platform supports a wide range of critical use cases, validating GenAI applications and chatbots, screening LLMs, assessing third-party AI risks, and ensuring compliance with regulations, such as the EU AI Act.

Advancing Evidence-Based EU AI Act Compliance

Building on its role as co-creator of COMPL-AI, the first framework to map EU AI Act principles to concrete technical controls, LatticeFlow AI is at the forefront of advancing evidence-based compliance. Most recently, the company delivered the first EU AI Act compliance-centered analysis of the Swiss LLM Apertus, which became the first large AI model compliant with the EU AI Act, further demonstrating its ability to translate regulatory principles into transparent, auditable technical assessments enterprises can rely on.

“The EU AI Act is a turning point for the industry,” added Dr. Tsankov. “It demands concrete technical evidence that AI systems are safe and trustworthy. With AI GO!, we help enterprises meet compliance head-on while continuing to drive innovation and value.”

Broad Industry Support

LatticeFlow AI’s industry leadership was recently highlighted at Trustworthy AI in Practice, a flagship event co-hosted with ETH Zurich last September 9th. The event underscored LatticeFlow AI’s deep scientific roots and its unique ability to convey the full AI ecosystem.

The event was a resounding success, uniting thought leaders from academia, industry, big tech, and enterprises to advance the discussion on making trustworthy AI a reality.

A key takeaway from the event was the pressing need for AI governance operations. Adrian Ott, Chief AI Officer at EY Switzerland, highlighted: “For successful AI transformation in businesses, it's crucial that AI innovation and risk management work in tandem rather than operating in opposition.”

Dr. Matthias Bossardt, Partner and Head of Cyber & Digital Risk at KPMG Switzerland, added: “To benefit from AI at scale, organizations must establish robust AI governance processes that enable efficient risk and performance monitoring.”

From the research and innovation view, Dr. Imanol Schlag, Technical Lead of the recently launched Swiss LLM Apertus, stressed: “The Swiss AI Initiative proves that large-scale efforts don't have to choose between capability and transparency.”

Finally, from a technology perspective, Dr. Naya Giannakopoulou, Senior Technical Architect at Microsoft Innovation Hub, remarked: “The future of enterprise-scale AI lies in guardrails that turn governance into an accelerator, not a blocker.”

Together, these perspectives reflect a shared vision: advancing AI governance through deep technical assessments that deliver trust, compliance, and innovation at scale.

About LatticeFlow AI

LatticeFlow AI sets a new standard in AI governance with deep technical assessments that enable evidence-based decisions and empower enterprises to accelerate their AI advantage.

As the creator of COMPL-AI, the world’s first EU AI Act framework for Generative AI developed with ETH Zurich and INSAIT, the company combines Swiss precision with scientific rigor to scale AI governance built on evidence and trust.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250917686559/en/

Contacts

Gloria Fernandez, Marketing Director, LatticeFlow AI - media@latticeflow.ai

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye